ZLAB vs RXRX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

ZLAB

61.1
AI Score
VS
ZLAB Wins

RXRX

50.6
AI Score

Investment Advisor Scores

ZLAB

61score
Recommendation
BUY

RXRX

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ZLAB RXRX Winner
Revenue 205.92M 14.14M ZLAB
Net Income -101.84M -248.51M ZLAB
Net Margin -49.5% -1757.1% ZLAB
Operating Income -145.87M -263.47M ZLAB
ROE -16.8% -27.2% ZLAB
ROA -9.5% -20.5% ZLAB
Total Assets 1.07B 1.21B RXRX
Cash 607.52M 545.68M ZLAB
Current Ratio 2.13 5.03 RXRX
Free Cash Flow -77.82M -187.35M ZLAB

Relative Price Performance (Last 90 Days)

ZLAB 1M: -8.4% · 3M: +23.0% RXRX 1M: -10.1% · 3M: +20.9%

Current Technical Phase

ZLAB

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 47.6 · Price: $24.20

RXRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 46.8 · Price: $3.64

Fundamentals Snapshot

Metric ZLAB RXRX
Market Cap — —
Forward P/E -11.5 -4.2
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% -0.6%
Gross Margin 0.0% -7.2%
Operating Margin -0.7% -17.6%
EPS -1.70 -1.00
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ZLAB is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.